IMMT抗体

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane 1-2: Hela cells, 231 cells, Primary antibody: P07380(IMMT Antibody) at dilution 1/250, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 1 minute    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colon cancer tissue using P07380(IMMT Antibody) at dilution 1/12. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human breast cancer tissue using P07380(IMMT Antibody) at dilution 1/12. (Original magnification: ×200)    

  
  

IMMT, also known as Mitofilin or MIC60. is a key component of the mitochondrial inner membrane organizing system (MINOS), crucial for maintaining mitochondrial cristae architecture. As a structural scaffold protein, IMMT facilitates the formation and stability of cristae junctions, ensuring proper organization of the electron transport chain and mitochondrial function. Dysregulation of IMMT has been linked to impaired oxidative phosphorylation, altered mitochondrial dynamics, and apoptosis.

Antibodies targeting IMMT are widely used in research to investigate mitochondrial morphology, bioenergetics, and disease mechanisms. They enable the detection of IMMT expression levels via Western blotting and visualization of its subcellular localization through immunofluorescence or immunoelectron microscopy. Studies employing IMMT antibodies have revealed its role in neurodegenerative diseases (e.g., Parkinson’s and Alzheimer’s), cancer (where its downregulation promotes metastasis), and metabolic disorders. Additionally, these antibodies help explore interactions between IMMT and other MINOS components (e.g., SAMM50. CHCHD3) or apoptotic regulators like F1Fo-ATP synthase.

The development of high-specificity, validated IMMT antibodies remains critical for advancing mitochondrial research, particularly in understanding how cristae remodeling impacts cellular health and therapeutic responses. Commercial antibodies are typically raised against conserved epitopes in humans, mice, or rats, allowing cross-species applicability in preclinical models.